DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) consists of 2,320 rigorously characterized, regulatory-approved compounds suitable for high-throughput and high-content screening (HTS/HCS) (Product Page). Each compound is pre-dissolved at 10 mM in DMSO, ensuring consistent assay conditions and streamlined integration into automated workflows. The library encompasses diverse drug classes, including receptor agonists, antagonists, enzyme inhibitors, and ion channel modulators, facilitating drug repositioning and mechanism-of-action studies across cancer, neurodegenerative, and infectious diseases (Yang et al., 2023). Empirical evidence demonstrates its utility in identifying actionable pharmacological targets, accelerating translational research, and mitigating challenges posed by drug resistance. The DiscoveryProbe™ library remains stable for up to 24 months at -80°C, supporting reproducible, long-term investigations.

Biological Rationale

High-throughput screening (HTS) and high-content screening (HCS) are core methodologies in modern drug discovery and repositioning. The use of libraries composed exclusively of FDA- and EMA-approved compounds increases translational potential by focusing on molecules with known safety, bioavailability, and clinical precedence (Yang et al., 2023). The DiscoveryProbe™ FDA-approved Drug Library is designed to support rapid identification of hits for new indications, particularly where resistance or limited efficacy is observed with standard-of-care therapies. By leveraging compounds with established pharmacokinetics and toxicity profiles, researchers can decrease the attrition rate in preclinical to clinical translation. The library supports studies in oncology, neurodegeneration, and rare diseases—fields where novel mechanisms and drug repositioning are highly sought (see also; this article extends by providing application-specific parameters and recent AML data).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library includes compounds that modulate a wide range of molecular targets. Mechanism classes represented include:

• Receptor agonists and antagonists (e.g., β-adrenergic agonists, opioid receptor antagonists)
• Enzyme inhibitors (e.g., kinase inhibitors, protease inhibitors, statins)
• Ion channel modulators (e.g., calcium channel blockers)
• Signal pathway regulators (e.g., mTOR, AMPK modulators)

For example, in a recent screen of 1,972 FDA-approved compounds, the TLR8 agonist Motolimod was identified as a potent inducer of caspase-3-dependent inflammatory cell death in acute myeloid leukemia (AML) cell lines, acting through TLR8 and LKB1/AMPK pathways (Yang et al., 2023). This approach exemplifies how the library enables identification of both canonical and novel mechanisms. Compounds are supplied in DMSO, compatible with most cell- and biochemical-based screening platforms, and are formatted for automated dispensing (cf., which provides a general overview; this article details mechanistic breadth and AML-specific findings).

Evidence & Benchmarks

• DiscoveryProbe™ L1021 comprises 2,320 unique bioactive compounds, each approved by at least one major regulatory agency (FDA, EMA, HMA, CFDA, or PMDA) or listed in a recognized pharmacopeia (ApexBio product doc).
• In a screen of 1,972 FDA-approved compounds, TLR8 agonist Motolimod was found to induce significant caspase-3-dependent cell death in AML cell lines while sparing normal lymphocytes (Yang et al. 2023, DOI).
• The library supports high-throughput screening workflows in 96-well and deep-well plate formats, compatible with automated liquid handling systems (ApexBio).
• Compound solutions are stable for 12 months at -20°C and 24 months at -80°C, ensuring integrity for repeated or longitudinal studies (ApexBio).
• Drug repositioning hits identified using the FDA-approved library have advanced to clinical evaluation in oncology and infectious disease (see Table 1, Yang et al. 2023).
• The library enables mechanism-of-action studies in rare and neglected disease models by providing reference drugs with defined targets (cf., which focuses on personalized medicine; this article expands on high-content screening and AML research).

Applications, Limits & Misconceptions

Key applications of the DiscoveryProbe™ FDA-approved Drug Library include:

• Drug repositioning screens in oncology, neurodegeneration, and infectious diseases
• Mechanism-of-action elucidation using annotated, approved molecules
• Pharmacological target identification for disease model validation
• Benchmarking novel screening assays against standardized compounds

While the library is highly versatile, it is not suited for all research needs. It contains only compounds with known regulatory or pharmacopeial status and does not include investigational or unapproved molecules.

Common Pitfalls or Misconceptions

• Not all disease targets are represented: The library is limited to compounds with prior regulatory or pharmacopeial approval; novel chemical space is excluded.
• Not for direct clinical use: Compounds are supplied for research only and are not GMP-certified for patient administration.
• Repositioning does not guarantee efficacy: Activity in screening assays does not always translate to in vivo or clinical success due to pharmacokinetics or toxicity issues.
• DMSO compatibility limits: Some cell types or assay systems may be sensitive to DMSO, requiring optimization of dilution protocols.
• Plate format constraints: While provided in multiple formats, large-scale or custom configurations may require additional handling or validation.

Workflow Integration & Parameters

DiscoveryProbe™ L1021 is optimized for seamless integration into automated HTS/HCS pipelines. Each compound is pre-dissolved at 10 mM in DMSO and arrayed in barcoded 96-well or deep-well plates, as well as in screw-top tubes with 2D barcodes. Recommended storage is -20°C for up to 12 months or -80°C for 24 months. For most cell-based screens, a final compound concentration of 1–10 μM is typical, with DMSO kept below 0.1% v/v. The library ships on blue ice for evaluation sizes and can be shipped at room temperature or on ice by request. Detailed plate maps and compound annotations are provided for assay setup and data management. Researchers can access compound metadata, including regulatory status, mechanism, and chemical structure, for downstream bioinformatics and machine learning applications (see also; this article provides updated workflow recommendations for recent screening platforms).

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) offers a robust, citation-backed foundation for translational research in pharmacological target identification, drug repositioning, and mechanistic studies. Its standardized, stable, and automation-ready format accelerates the pace of discovery and enables reproducible results across research domains. Recent evidence in AML and other models demonstrates the library's value in uncovering novel mechanisms and actionable targets (Yang et al. 2023). As disease biology and screening technologies evolve, curated, regulatory-approved compound libraries like DiscoveryProbe™ will remain essential tools for high-confidence, high-impact biomedical research. For further details or to request the L1021 kit, visit the DiscoveryProbe™ FDA-approved Drug Library product page.